Phio Pharmaceuticals Corp. has announced key pathology and safety data from its Phase 1b dose escalation clinical trial evaluating the INTASYL compound PH-762 for the treatment of skin cancer. The trial included 22 patients with cutaneous carcinomas across five dose-escalating cohorts. Results indicate a 70% overall response rate for squamous cell carcinomas (cSCC), with 10 out of 14 responders achieving complete clearance. The treatment was well tolerated, with no dose-limiting toxicities or clinically relevant treatment-emergent adverse effects reported. Safety data from an extended follow-up period is expected to be reported in the second quarter of 2026. The company is proceeding with the design of follow-on clinical trials based on these findings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phio Pharmaceuticals Corp. published the original content used to generate this news brief via Newsfile (Ref. ID: 280906) on January 20, 2026, and is solely responsible for the information contained therein.